Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.
via Wikipedia infobox
{{Infobox drug | image = Enzalutamide-01.svg | image_class = skin-invert-image | width = 250 | alt = | width2 = 250 | alt2 =
| pronounce = | tradename = Xtandi | Drugs.com = | MedlinePlus = a612033 | DailyMedID = Enzalutamide | pregnancy_AU = X | pregnancy_AU_comment = | routes_of_administration = By mouth | class = Nonsteroidal antiandrogen | ATC_prefix = L02 | ATC_suffix = BB04 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).